

Maine Medical Association
P. O. BOX 250
BRUNSWICK, MAINE 04011
TELEPHONE 725-6414

Executive Director
DANIEL E. HAYLEY, M.D.

Secretary-Treasurer
ROBERT M. KENNAED

February 3, 1969

Dear Doctor:

You may be aware of the FDA order to withdraw Mysteclin-F from the market due to the NAS/NRC panel's report on Mysteclin-F, indicating that they are not aware of evidence of proved efficacy in the prevention of disease due to monilia organisms, although suppression of growth of monilia may be accomplished.

- IF you believe Mysteclin-F has had a definite useful place among the antibiotics prescribed in your practice, particularly for those types of patients prone to candidal infections (women with a history of candidiasis, elderly patients, debilitated patients, diabetics, patients on corticosteroids, etc);
- IF your medical opinion is that spread of intestinal candida to cause candidiasis is a risk which in the indicated conditions should be considered in using antibiotic therapy;
- IF you feel that the combination contained in Mysteclin-F in your experience is convenient, useful, effective and of definite value in the care of your patients;
- IF you feel the FDA order to withdraw Mysteclin-F from availability for prescription use would create an unnecessary and inconvenient restriction on your prescribing freedom to the detriment of your patients

Please forward your opinion to:

Herbert L. Ley, Jr., M.D.
Commissioner of Food and Drugs
Department of Health, Education
and Welfare
Washington, D.C. 20204

*no choice on this form for those supporting the
FDA order - since this may tend to result in a
biased impression (because ^{most} would simply not)*

Printed in Maine, June 15-17, 1969